Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Visual Experience-Dependent Expression of Fn14 Is Required for Retinogeniculate Refinement.

Cheadle L, Tzeng CP, Kalish BT, Harmin DA, Rivera S, Ling E, Nagy MA, Hrvatin S, Hu L, Stroud H, Burkly LC, Chen C, Greenberg ME.

Neuron. 2018 Aug 8;99(3):525-539.e10. doi: 10.1016/j.neuron.2018.06.036. Epub 2018 Jul 19.

2.

Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.

May-Dracka TL, Arduini R, Bertolotti-Ciarlet A, Bhisetti G, Brickelmaier M, Cahir-McFarland E, Enyedy I, Fontenot JD, Hesson T, Little K, Lyssikatos J, Marcotte D, McKee T, Murugan P, Patterson T, Peng H, Rushe M, Silvian L, Spilker K, Wu P, Xin Z, Burkly LC.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1964-1971. doi: 10.1016/j.bmcl.2018.03.032. Epub 2018 Mar 26.

PMID:
29636220
3.

Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.

Chamberlain C, Colman PJ, Ranger AM, Burkly LC, Johnston GI, Otoul C, Stach C, Zamacona M, Dörner T, Urowitz M, Hiepe F.

Ann Rheum Dis. 2017 Nov;76(11):1837-1844. doi: 10.1136/annrheumdis-2017-211388. Epub 2017 Aug 5. Erratum in: Ann Rheum Dis. 2018 May;77(5):787-788.

PMID:
28780512
4.
5.

Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing.

Vollmann EH, Cao L, Amatucci A, Reynolds T, Hamann S, Dalkilic-Liddle I, Cameron TO, Hossbach M, Kauffman KJ, Mir FF, Anderson DG, Novobrantseva T, Koteliansky V, Kisseleva T, Brenner D, Duffield J, Burkly LC.

Mol Ther Nucleic Acids. 2017 Jun 16;7:314-323. doi: 10.1016/j.omtn.2017.04.014. Epub 2017 Apr 20.

6.

Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus.

Pejchinovski M, Siwy J, Mullen W, Mischak H, Petri MA, Burkly LC, Wei R.

Lupus. 2018 Jan;27(1):6-16. doi: 10.1177/0961203317707827. Epub 2017 May 5.

7.

Disruption of the TWEAK/Fn14 pathway prevents 5-fluorouracil-induced diarrhea in mice.

Sezaki T, Hirata Y, Hagiwara T, Kawamura YI, Okamura T, Takanashi R, Nakano K, Tamura-Nakano M, Burkly LC, Dohi T.

World J Gastroenterol. 2017 Apr 7;23(13):2294-2307. doi: 10.3748/wjg.v23.i13.2294.

8.

Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology.

Wei R, Gao B, Shih F, Ranger A, Dearth A, Mischak H, Siwy J, Wisniacki N, Petri M, Burkly LC.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1468-1477. doi: 10.1093/ndt/gfw446.

PMID:
28339802
9.

PDGF-BB Promotes Type I IFN-Dependent Vascular Alterations and Monocyte Recruitment in a Model of Dermal Fibrosis.

Cho JS, Fang TC, Reynolds TL, Sofia DJ, Hamann S, Burkly LC.

PLoS One. 2016 Sep 12;11(9):e0162758. doi: 10.1371/journal.pone.0162758. eCollection 2016.

10.

A Novel Role for TL1A/DR3 in Protection against Intestinal Injury and Infection.

Jia LG, Bamias G, Arseneau KO, Burkly LC, Wang EC, Gruszka D, Pizarro TT, Cominelli F.

J Immunol. 2016 Jul 1;197(1):377-86. doi: 10.4049/jimmunol.1502466. Epub 2016 May 27.

11.

TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease.

Gomez IG, Roach AM, Nakagawa N, Amatucci A, Johnson BG, Dunn K, Kelly MC, Karaca G, Zheng TS, Szak S, Peppiatt-Wildman CM, Burkly LC, Duffield JS.

J Am Soc Nephrol. 2016 Dec;27(12):3639-3652. Epub 2016 Mar 29.

12.

Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation.

Wilhelm A, Shepherd EL, Amatucci A, Munir M, Reynolds G, Humphreys E, Resheq Y, Adams DH, Hübscher S, Burkly LC, Weston CJ, Afford SC.

J Pathol. 2016 May;239(1):109-21. doi: 10.1002/path.4707. Epub 2016 Mar 29.

13.

Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival.

Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P, Weston R, Jayatilleke KM, Schloegel J, Talbo G, Casey JL, Levina V, Wong WW, Dillon H, Sahay T, Hoogenraad J, Anderton H, Hall C, Schneider P, Tanzer M, Foley M, Scott AM, Gregorevic P, Liu SY, Burkly LC, Lynch GS, Silke J, Hoogenraad NJ.

Cell. 2015 Sep 10;162(6):1365-78. doi: 10.1016/j.cell.2015.08.031.

14.

TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice.

Wen J, Doerner J, Weidenheim K, Xia Y, Stock A, Michaelson JS, Baruch K, Deczkowska A, Gulinello M, Schwartz M, Burkly LC, Putterman C.

J Autoimmun. 2015 Jun;60:40-50. doi: 10.1016/j.jaut.2015.03.005. Epub 2015 Apr 22.

15.

TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus.

Doerner JL, Wen J, Xia Y, Paz KB, Schairer D, Wu L, Chalmers SA, Izmirly P, Michaelson JS, Burkly LC, Friedman AJ, Putterman C.

J Invest Dermatol. 2015 Aug;135(8):1986-1995. doi: 10.1038/jid.2015.124. Epub 2015 Mar 31.

16.

Regulation of Tissue Responses: The TWEAK/Fn14 Pathway and Other TNF/TNFR Superfamily Members That Activate Non-Canonical NFκB Signaling.

Burkly LC.

Front Immunol. 2015 Mar 2;6:92. doi: 10.3389/fimmu.2015.00092. eCollection 2015. No abstract available.

17.

Tweak regulates astrogliosis, microgliosis and skeletal muscle atrophy in a mouse model of amyotrophic lateral sclerosis.

Bowerman M, Salsac C, Coque E, Eiselt É, Deschaumes RG, Brodovitch A, Burkly LC, Scamps F, Raoul C.

Hum Mol Genet. 2015 Jun 15;24(12):3440-56. doi: 10.1093/hmg/ddv094. Epub 2015 Mar 12.

PMID:
25765661
18.

Role of Fn14 in acute alcoholic steatohepatitis in mice.

Karaca G, Xie G, Moylan C, Swiderska-Syn M, Guy CD, Krüger L, Machado MV, Choi SS, Michelotti GA, Burkly LC, Diehl AM.

Am J Physiol Gastrointest Liver Physiol. 2015 Feb 15;308(4):G325-34. doi: 10.1152/ajpgi.00429.2013. Epub 2014 Dec 18.

19.

Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis.

Xia Y, Herlitz LC, Gindea S, Wen J, Pawar RD, Misharin A, Perlman H, Wu L, Wu P, Michaelson JS, Burkly LC, Putterman C.

J Am Soc Nephrol. 2015 May;26(5):1053-70. doi: 10.1681/ASN.2014030233. Epub 2014 Sep 30.

20.

Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice.

Tarín C, Fernández-Laso V, Sastre C, Madrigal-Matute J, Gómez M, Zaragoza C, Egido J, Burkly LC, Martín-Ventura JL, Blanco-Colio LM.

J Am Heart Assoc. 2014 Aug 4;3(4). pii: e000723. doi: 10.1161/JAHA.113.000723. Erratum in: J Am Heart Assoc. 2014 Oct;3(5):000509.

21.

Pathological activation of canonical nuclear-factor κB by synergy of tumor necrosis factor α and TNF-like weak inducer of apoptosis in mouse acute colitis.

Dohi T, Kawashima R, Kawamura YI, Otsubo T, Hagiwara T, Amatucci A, Michaelson J, Burkly LC.

Cytokine. 2014 Sep;69(1):14-21. doi: 10.1016/j.cyto.2014.05.001. Epub 2014 May 27.

PMID:
25022957
22.

TNF-like weak inducer of apoptosis aggravates left ventricular dysfunction after myocardial infarction in mice.

Jarr KU, Eschricht S, Burkly LC, Preusch M, Katus HA, Frey N, Chorianopoulos E.

Mediators Inflamm. 2014;2014:131950. doi: 10.1155/2014/131950. Epub 2014 Feb 20.

23.

The TWEAK-Fn14 dyad is involved in age-associated pathological changes in skeletal muscle.

Tajrishi MM, Sato S, Shin J, Zheng TS, Burkly LC, Kumar A.

Biochem Biophys Res Commun. 2014 Apr 18;446(4):1219-1224. doi: 10.1016/j.bbrc.2014.03.084. Epub 2014 Mar 26.

24.

TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities.

Burkly LC.

Semin Immunol. 2014 Jun;26(3):229-36. doi: 10.1016/j.smim.2014.02.006. Epub 2014 Mar 11. Review.

PMID:
24636536
25.

Deletion of TNF-like weak inducer of apoptosis (TWEAK) protects mice from adipose and systemic impacts of severe obesity.

Bennett G, Strissel KJ, DeFuria J, Wang J, Wu D, Burkly LC, Obin MS.

Obesity (Silver Spring). 2014 Jun;22(6):1485-94. doi: 10.1002/oby.20726. Epub 2014 Mar 8.

26.

Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice.

Sastre C, Fernández-Laso V, Madrigal-Matute J, Muñoz-García B, Moreno JA, Pastor-Vargas C, Llamas-Granda P, Burkly LC, Egido J, Martín-Ventura JL, Blanco-Colio LM.

J Cell Mol Med. 2014 Apr;18(4):721-34. doi: 10.1111/jcmm.12221. Epub 2014 Jan 30.

27.

The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease.

Tajrishi MM, Zheng TS, Burkly LC, Kumar A.

Cytokine Growth Factor Rev. 2014 Apr;25(2):215-25. doi: 10.1016/j.cytogfr.2013.12.004. Epub 2013 Dec 24. Review.

28.

TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice.

Karaca G, Swiderska-Syn M, Xie G, Syn WK, Krüger L, Machado MV, Garman K, Choi SS, Michelotti GA, Burkly LC, Ochoa B, Diehl AM.

PLoS One. 2014 Jan 9;9(1):e83987. doi: 10.1371/journal.pone.0083987. eCollection 2014.

29.

Regulatory circuitry of TWEAK-Fn14 system and PGC-1α in skeletal muscle atrophy program.

Hindi SM, Mishra V, Bhatnagar S, Tajrishi MM, Ogura Y, Yan Z, Burkly LC, Zheng TS, Kumar A.

FASEB J. 2014 Mar;28(3):1398-411. doi: 10.1096/fj.13-242123. Epub 2013 Dec 10.

30.

Fn14 in podocytes and proteinuric kidney disease.

Sanchez-Niño MD, Poveda J, Sanz AB, Mezzano S, Carrasco S, Fernandez-Fernandez B, Burkly LC, Nair V, Kretzler M, Hodgin JB, Ruiz-Ortega M, Selgas R, Egido J, Ortiz A.

Biochim Biophys Acta. 2013 Dec;1832(12):2232-43. doi: 10.1016/j.bbadis.2013.08.010. Epub 2013 Aug 30.

31.

TNF-like weak inducer of apoptosis (TWEAK) promotes beta cell neogenesis from pancreatic ductal epithelium in adult mice.

Wu F, Guo L, Jakubowski A, Su L, Li WC, Bonner-Weir S, Burkly LC.

PLoS One. 2013 Aug 26;8(8):e72132. doi: 10.1371/journal.pone.0072132. eCollection 2013.

32.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.

Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, Burkly LC.

Clin Ther. 2013 Aug;35(8):1137-49. doi: 10.1016/j.clinthera.2013.06.008. Epub 2013 Aug 6.

PMID:
23928094
33.

A further TWEAK to multiple sclerosis pathophysiology.

Nazeri A, Heydarpour P, Sadaghiani S, Sahraian MA, Burkly LC, Bar-Or A.

Mol Neurobiol. 2014 Feb;49(1):78-87. doi: 10.1007/s12035-013-8490-y. Epub 2013 Jul 20. Review.

PMID:
23873135
34.

TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast.

Ucero AC, Benito-Martin A, Fuentes-Calvo I, Santamaria B, Blanco J, Lopez-Novoa JM, Ruiz-Ortega M, Egido J, Burkly LC, Martinez-Salgado C, Ortiz A.

Biochim Biophys Acta. 2013 Oct;1832(10):1744-55. doi: 10.1016/j.bbadis.2013.05.032. Epub 2013 Jun 6.

35.

Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway.

Wen J, Xia Y, Stock A, Michaelson JS, Burkly LC, Gulinello M, Putterman C.

J Autoimmun. 2013 Jun;43:44-54. doi: 10.1016/j.jaut.2013.03.002. Epub 2013 Apr 8.

36.

TWEAK/Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice.

Son A, Oshio T, Kawamura YI, Hagiwara T, Yamazaki M, Inagaki-Ohara K, Okada T, Wu P, Iseki M, Takaki S, Burkly LC, Dohi T.

Mucosal Immunol. 2013 Nov;6(6):1131-42. doi: 10.1038/mi.2013.10. Epub 2013 Mar 6.

PMID:
23462911
37.

PGC1α plays a critical role in TWEAK-induced cardiac dysfunction.

Shi J, Jiang B, Qiu Y, Guan J, Jain M, Cao X, Bauer M, Su L, Burkly LC, Leone TC, Kelly DP, Liao R.

PLoS One. 2013;8(1):e54054. doi: 10.1371/journal.pone.0054054. Epub 2013 Jan 16.

38.

HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes.

Moreno JA, Sastre C, Madrigal-Matute J, Muñoz-García B, Ortega L, Burkly LC, Egido J, Martín-Ventura JL, Blanco-Colio LM.

Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):612-20. doi: 10.1161/ATVBAHA.112.300874. Epub 2013 Jan 3.

PMID:
23288170
39.

Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis.

Xia Y, Campbell SR, Broder A, Herlitz L, Abadi M, Wu P, Michaelson JS, Burkly LC, Putterman C.

Clin Immunol. 2012 Nov;145(2):108-21. doi: 10.1016/j.clim.2012.08.008. Epub 2012 Aug 20.

40.

Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Michaelson JS, Wisniacki N, Burkly LC, Putterman C.

J Autoimmun. 2012 Sep;39(3):130-42. doi: 10.1016/j.jaut.2012.05.003. Epub 2012 Jun 22. Review.

41.

The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases.

Dohi T, Burkly LC.

J Leukoc Biol. 2012 Aug;92(2):265-79. doi: 10.1189/jlb.0112042. Epub 2012 Jun 6. Review.

PMID:
22672874
42.

TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses.

Burkly LC, Michaelson JS, Zheng TS.

Immunol Rev. 2011 Nov;244(1):99-114. doi: 10.1111/j.1600-065X.2011.01054.x. Review.

PMID:
22017434
43.

Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis.

Kawashima R, Kawamura YI, Oshio T, Son A, Yamazaki M, Hagiwara T, Okada T, Inagaki-Ohara K, Wu P, Szak S, Kawamura YJ, Konishi F, Miyake O, Yano H, Saito Y, Burkly LC, Dohi T.

Gastroenterology. 2011 Dec;141(6):2119-2129.e8. doi: 10.1053/j.gastro.2011.08.040. Epub 2011 Sep 3.

PMID:
21893119
44.

Development of an Fn14 agonistic antibody as an anti-tumor agent.

Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, Berquist L, Cho S, Li Y, Parr M, Wille L, Schneider P, Wortham K, Burkly LC, Hsu YM, Joseph IB.

MAbs. 2011 Jul-Aug;3(4):362-75. Epub 2011 Jul 1.

45.

Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma.

Kennedy DR, Hartnett BJ, Kennedy JS, Vernau W, Moore PF, O'Malley T, Burkly LC, Henthorn PS, Felsburg PJ.

Vet Immunol Immunopathol. 2011 Jul 15;142(1-2):36-48. doi: 10.1016/j.vetimm.2011.04.003. Epub 2011 Apr 14.

46.

The TWEAK/Fn14 pathway in tissue remodeling: for better or for worse.

Burkly LC, Dohi T.

Adv Exp Med Biol. 2011;691:305-22. doi: 10.1007/978-1-4419-6612-4_32. Review. No abstract available.

PMID:
21153335
47.

Introductory words about TWEAK/Fn14.

Burkly LC.

Adv Exp Med Biol. 2011;691:275-7. doi: 10.1007/978-1-4419-6612-4_28. No abstract available.

PMID:
21153331
48.

TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells.

Muñoz-García B, Madrigal-Matute J, Moreno JA, Martin-Ventura JL, López-Franco O, Sastre C, Ortega L, Burkly LC, Egido J, Blanco-Colio LM.

Cardiovasc Res. 2011 Jan 1;89(1):225-33. doi: 10.1093/cvr/cvq278. Epub 2010 Sep 1.

PMID:
20810696
49.

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C.

Arthritis Res Ther. 2009;11(5):R143. doi: 10.1186/ar2816. Epub 2009 Sep 28.

50.

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice.

Muñoz-García B, Moreno JA, López-Franco O, Sanz AB, Martín-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J, Blanco-Colio LM.

Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2061-8. doi: 10.1161/ATVBAHA.109.194852. Epub 2009 Sep 24.

PMID:
19778942

Supplemental Content

Loading ...
Support Center